A phase I double-blind, randomized, placebo-controlled, single-ascending dose study to evaluate the Safety and Pharmacokinetics of SAR-252067
Latest Information Update: 12 Nov 2016
At a glance
- Drugs Quisovalimab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sanofi
- 12 Nov 2016 New trial record